<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Overman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Morse, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3581551962"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Deficient mismatch repair (dMMR) and its characteristic genetic signature, high levels of microsatellite instability (MSI-H) across the genome, define a unique biologic subset of cancers that are characterized by a high tumor mutational load and potential responsiveness to anti-programmed cell death 1 (PD-1)-based immune checkpoint inhibitor immunotherapy. Other mechanisms of high tumor mutational load or burden (ie, tumor mutational burden [TMB]) may also render tumors sensitive to immune checkpoint blockade.</p><p>This topic provides an overview of the biology of dMMR and TMB, reviews methods to assess dMMR and TMB, the frequency of dMMR/MSI-H and TMB in a variety of tumor types, and summarizes data on the comparative clinical efficacy of immune checkpoint inhibitor immunotherapy in colorectal and noncolorectal cancers with dMMR and high levels of TMB in patients with advanced cancer. An overview of cancer immunotherapy is provided elsewhere. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p class="headingAnchor" id="H2281452263"><span class="h1">BIOLOGY OF MISMATCH REPAIR AND TUMOR MUTATIONAL BURDEN</span><span class="headingEndMark"> — </span>Mutations in one of the DNA mismatch repair (MMR) genes are found in the germline of individuals with Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) and in the minority of the 15 percent of sporadic colon cancers that have loss of DNA MMR (most of the defects in sporadic colorectal cancer are due to promoter hypermethylation of MLH1 rather than a mutation in a DNA MMR gene).</p><p>There are four relevant mismatch repair genes: mutL homolog 1 (<em>MLH1</em>), mutS homolog 2 (<em>MSH2</em>), mutS homolog 6 (<em>MSH6</em>), and postmeiotic segregation increased 2 (<em>PMS2</em>). Further, mutations in the 3' end of the epithelial cell adhesion molecule (<em>EPCAM</em>) gene can cause Lynch syndrome through promoter methylation-induced inactivation of the downstream <em>MSH2</em> gene. (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Genetics'</a> and  <a class="medical medical_review" href="/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer", section on 'Mismatch repair genes'</a>.)</p><p>Mismatch repair is one of a cell's mechanisms for repairing damage to DNA that primarily results from single base pair insertions or deletions (called indels) when slippage occurs during DNA replication by DNA polymerases. This type of DNA polymerase error tends to occur at areas of short, repetitive DNA sequences, termed microsatellites. Therefore, deficient mismatch repair (dMMR) can be discovered by looking at the variation in the length of a microsatellite in normal tissue compared with its length in the same patient's tumor tissue. When a high rate of variation in microsatellite length exists across the genome, a tumor is said to have high levels of microsatellite instability (MSI-H), which reflects underlying deficiency in mismatch repair capability. (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Genetics'</a>.)</p><p>As expected, an inability to repair DNA damage results in the accumulation of mutations. Tumors that lack the mismatch repair mechanism harbor many more mutations (ie, they are hypermutated) than do tumors of the same type without such mismatch repair defects [<a href="#rid1">1,2</a>]. Invariably, almost all tumors with dMMR demonstrate a high tumor mutation burden (TMB) [<a href="#rid3">3,4</a>]. As an example, an analysis of 62,150 cancer samples analyzed by a large next-generation sequencing panel demonstrated 699 cases to have MSI-H and high TMB (defined in this study as ≥20 mutations per megabase [mut/Mb]) [<a href="#rid3">3</a>]. The vast majority of MSI-H cases (83 percent) also had high TMB, with 97 percent having TMB ≥10 mut/Mb.</p><p>Although most MSI-H tumors are TMB-high, not all TMB-high cases are MSI-H. (See <a class="local">'Tumor mutational burden'</a> below.)</p><p>These mutations code for mutant proteins, which, like other cell proteins, are recycled via the immunoproteasome pathway. A minority of these mutations can give rise to neoantigens, mutation-derived antigens that can be recognized by CD8+ T cells, and targeted by the immune system in vivo [<a href="#rid5">5-8</a>].</p><p>The greater immunogenicity of mutations generated by dMMR relates to the nature of single base pair insertions and deletions, which lead to frameshift mutations that may generate not one amino acid alteration but a sequence of multiple altered amino acids, creating an amino acid sequence "foreign" to the person. Some of these peptide sequences can then be presented by a person's human leukocyte antigen (HLA) class I molecules, generating novel antigens or "neoantigens." This is illustrated by a large dataset of 619 colorectal cancers (of all molecular subtypes) that underwent DNA exome sequencing in which the rate of mutations and the rate of high-affinity neoantigens predicted to bind to HLA class I were determined [<a href="#rid9">9</a>]. While frameshift indels represented 8.1 percent of the mutations, these same mutations represented 22.6 percent of the predicted neoantigens.</p><p class="headingAnchor" id="H1255024231"><span class="h2">Checkpoint inhibitors, deficient mismatch repair, and the immune response to cancer</span><span class="headingEndMark"> — </span>Immunotherapeutic approaches to cancer therapy are based on the premise that the immune system plays a key role in the surveillance and eradication of malignancy, and that tumors evolve ways to elude the immune system. The same tolerance mechanisms that suppress the immune response to self-antigens to minimize autoimmune disease may also serve to blunt the immune response to these tumor antigens in vivo [<a href="#rid10">10</a>]. Based on data on the immunogenicity of mutated antigens in melanoma, it has been hypothesized that the "neoantigens" generated from tumor-specific mutations of self-antigens within certain cancers may be recognized by the immune system as foreign and could therefore trigger an antitumor immune response. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>Several steps are required for the immune system to effectively attack tumor cells. These include tumor antigen uptake by antigen-presenting cells, such as dendritic cells, presentation of the tumor antigen to T cells, T cell activation and trafficking to the tumor, and direct attack of the tumor. Several immune checkpoints exist to dampen the immune response in order to protect against detrimental inflammation and autoimmunity. In the setting of malignancy, such immune checkpoints can result in immune tolerance to the tumor allowing escape from the immune response and progression of the malignancy. Inhibition of these checkpoints might be expected to halt/reverse disease progression. One well-characterized checkpoint being targeted in several tumor types is programmed cell death 1 (PD-1). PD-1 is upregulated on activated T cells, and upon recognition of tumor via the T cell receptor, PD-1 engagement by programmed cell death ligand 1 (PD-L1) expressed by tumor or other immune cells infiltrating the tumor tissue can lead to T cell inactivation and a "brake" on immune-mediated tumor eradication. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>Proof of principle that cancers with dMMR might be particularly susceptible to inhibition of the PD-L1/PD-1 interaction was initially provided by a study of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in dMMR colorectal cancer, and subsequently shown in a variety of tumor types. These data are described in detail below. (See <a class="local">'Clinical efficacy of anti-PD-1 therapy'</a> below.)</p><p class="headingAnchor" id="H2103911377"><span class="h2">Tumor mutational burden</span><span class="headingEndMark"> — </span>As noted above, tumors with high mutational burden (particularly those arising in the setting of dMMR) are thought to be more immunogenic and responsive to immune checkpoint inhibitor immunotherapy. (See <a class="local">'Checkpoint inhibitors, deficient mismatch repair, and the immune response to cancer'</a> above.)</p><p>The vast majority of dMMR tumors have high TMB, with the median number of mutations often in the thousands. However, not all TMB-high tumors have dMMR [<a href="#rid3">3</a>], and in these cases, the number of mutations is much lower, approximately 200 nonsynonymous mutations (ie, coding variants that alter the amino acid composition of a protein) per exome (which is equivalent to approximately 10 mut/Mb on the FoundationOne CDx platform) [<a href="#rid11">11-14</a>]. (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms", section on 'Coding mutation, variant, or polymorphism'</a>.)</p><p>Given these issues, TMB has been of increasing interest as a potential biomarker of benefit from immune checkpoint inhibitor immunotherapy beyond dMMR. In several retrospective studies, performed in different types of cancer, the hypothesis of correlation between high TMB and better response to immune checkpoint inhibitors seems to be validated [<a href="#rid14">14-19</a>]. However, the relationship between TMB and response to immune checkpoint inhibitors is imperfect across and within tumor types. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Merkel cell carcinomas, renal cell cancers, and mesothelioma all have higher response rates to immune checkpoint inhibitors than would be anticipated from their TMBs [<a href="#rid20">20-22</a>]. (See <a class="local">'Tumors with high mutational burden'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TMB has a poor predictive value for response to immune checkpoint inhibitors in some tumor types such as glioma and microsatellite stable colorectal and gastroesophageal cancer [<a href="#rid23">23-25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although a meta-analysis suggests that TMB predicts benefit for combined therapy that targets two different immune checkpoints (cytotoxic T-cell associated antigen-4 and PD-1/PD-L1) [<a href="#rid26">26</a>], individual studies have not always shown this association [<a href="#rid14">14</a>]. (See <a class="local">'Tumors with high mutational burden'</a> below.)</p><p></p><p>A major problem is that the approach for determination of TMB and the TMB thresholds predicting response to immune checkpoint blockade have been developed independently in each tumor type. Further, they are likely to differ across tumor types [<a href="#rid27">27,28</a>] and also across testing platforms (eg, blood versus tumor tissue [<a href="#rid29">29,30</a>]), even within a particular tumor; thus, no consistent pan-cancer testing approach has been validated. Efforts are underway to harmonize the assessment of TMB across different tumor types and platforms [<a href="#rid29">29,31</a>]. (See <a class="local">'Approach to testing for high levels of TMB'</a> below.)</p><p>Nevertheless, in June 2020, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was approved for unresectable or metastatic TMB-high (≥10 mut/Mb) solid tumors, as determined by a US Food and Drug Administration-approved test, although the FoundationOne CDx assay was the platform used in the supporting KEYNOTE-158 study. The approval was largely based on response rate and not benefits in more meaningful clinical endpoints. Subsequently, concerns have been raised as to whether this approval is too broad and whether immune checkpoint inhibitors should be considered in the context of the cause of the high TMB and not based solely on an absolute threshold [<a href="#rid32">32</a>].</p><p>However, whether all patients with high levels of TMB benefit is unclear. At least some data (predominantly in advanced colorectal cancer) suggest that benefit in this setting may be limited to patients with high TMB and either dMMR or a <em>POLE or POLD1</em> (collectively referred to as <em>pol-d</em>) pathogenic mutations [<a href="#rid32">32-34</a>]. (See  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'MMR-proficient tumors with high tumor mutational burden'</a>.)</p><p>The available prospective trials addressing the benefits of TMB as a predictor of benefit from immune checkpoint inhibitors are discussed below. (See <a class="local">'Tumors with high mutational burden'</a> below.)</p><p class="headingAnchor" id="H4012227755"><span class="h1">ASSESSING MISMATCH REPAIR</span></p><p class="headingAnchor" id="H2827847265"><span class="h2">Specific tests</span><span class="headingEndMark"> — </span>Classically, deficient mismatch repair (dMMR) has been assessed by either direct immunohistochemical testing (IHC) for loss of the various mismatch repair proteins (mutL homolog 1 [MLH1], mutS homolog 2 [MSH2], mutS homolog 6 [MHS6], and postmeiotic segregation increased 2 [PMS2]) or by a comparison of the variation in length of a limited number of microsatellites between normal and tumor tissue by polymerase chain reaction (PCR). It can also be assessed by next-generation sequencing (NGS). For patients with colorectal cancer, assessment by any of these methods is acceptable [<a href="#rid35">35</a>]. For cancers other than colorectal cancer, we recommend the use of IHC or NGS panels rather than PCR for microsatellite instability when evaluating for dMMR/high levels of microsatellite instability (MSI-H) due to the potentially lower sensitivity of PCR in other tumor types.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunohistochemistry</strong> – Mutations in the mismatch repair genes that cause Lynch syndrome, and biallelic mutations in mismatch repair genes or hypermethylation of the MLH1 promotor in sporadic dMMR colon cancers typically result in a truncated or lost mismatch repair protein that can be detected as a <strong>loss of staining of the protein</strong> on tumor IHC. (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Immunohistochemistry'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCR</strong> – Microsatellite instability testing is performed using PCR to amplify a standard panel of DNA sequences containing nucleotide repeats. In the most commonly used panel (which includes two mononucleotides [BAT25 and BAT26] and three dinucleotides [D2S123, D5S346, and D17S250] [<a href="#rid36">36-38</a>]), if 30 percent or more of the markers show expansion or contraction of the repetitive sequences in the tumor compared with the normal mucosa from the same patient, the tumor is reported to have MSI-H. These microsatellites were chosen based on the desire to identify the inherited cause of dMMR (Lynch syndrome) in patients with colorectal cancer. (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Immunohistochemistry'</a> and  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Next-generation sequencing (NGS) panels</strong> – As of more recently, microsatellite instability testing can be performed with NGS panels. As there are thousands of microsatellites through the genome, readily captured with NGS methods, laboratories have developed different methods of gauging the level of variation at these microsatellites. There are multiple commercially available NGS testing panels (such as Caris Life Sciences, Foundation Medicine, Guardant360, or Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) that determine MSI-H status based on a comparison of the microsatellites sequenced [<a href="#rid4">4,39-41</a>]. In each platform, the specific microsatellites analyzed vary, and the statistical methodologies determining variation in length are unique; however, all panels have demonstrated excellent sensitivity and specificity when compared with either PCR-determined MSI-H status [<a href="#rid42">42-44</a>] or IHC-based dMMR determination.</p><p></p><p class="bulletIndent1">In fact, the larger number of microsatellites evaluated using NGS may lead to improved detection of MSI-H across different tumor types, as data have demonstrated that the variation in length of microsatellites is tissue specific, with different tumor types demonstrating different predilections for altered microsatellites. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a large exome analysis of 617 gastric, colorectal, and endometrial cases, MSI-H using exome data was compared with that using PCR detection and demonstrated a sensitivity of 95.8 percent and a specificity of 97.6 percent [<a href="#rid45">45</a>]. However, in 7 of the 16 discrepant cases, additional data demonstrated the exome MSI-H determination to be correct and the PCR determination to be incorrect.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another series of 91 prostate cancer patients, MSI-H by an NGS panel was compared with MSI-H by PCR, using biallelic inactivating mutations in mismatch repair genes as the gold standard. Using this gold standard, 29 patients had dMMR, and 62 had proficient mismatch repair (pMMR). The sensitivity and specificity for detection of dMMR were 93.1 and 94 percent for NGS and 72.4 and 100 percent for PCR [<a href="#rid46">46</a>].</p><p></p><p>These findings suggest that a specific, limited PCR panel devised primarily for colorectal cancer would likely demonstrate suboptimal performance across other tumor types, and that the use of IHC or NGS panels is preferred when evaluating for dMMR/MSI-H in noncolorectal cancers.</p><p class="headingAnchor" id="H1449502784"><span class="h2">Frequency of dMMR across tumor types</span><span class="headingEndMark"> — </span>The rate of deficient mismatch repair (dMMR) cancers has been established from a large-scale analysis of 11,139 tumor-normal pairs, primarily derived from The Cancer Genome Atlas (TCGA), covering 39 different cancer types  (<a class="graphic graphic_figure graphicRef120779" href="/d/graphic/120779.html" rel="external">figure 1</a>) [<a href="#rid47">47</a>]. In this analysis, which was performed mainly on primary tumors, the prevalence of MSI-H extended from 31.4 percent in endometrial carcinomas to 0.25 percent in glioblastoma. Cases of MSI-H were detected in 27 cancer types, 12 of which had a prevalence greater than 1 percent. The top 10 cancers with the highest prevalence were uterine endometrial carcinoma, colon adenocarcinoma, stomach adenocarcinoma, rectal adenocarcinoma, adrenocortical carcinoma, uterine carcinosarcoma, cervical cancer, Wilms tumor, mesothelioma, and esophageal carcinoma.</p><p>As dMMR cancers tend to have a good prognosis as localized tumors with a lower rate of developing metastases, the rate of dMMR in stage I to III cancers tends to be higher than that seen in stage IV or metastatic cases. Given that anti-programmed cell death 1 (PD-1) therapy is used for the treatment of dMMR patients with metastatic disease, the prevalence of dMMR/MSI-H across metastatic cancers is of greatest relevance to clinical care. These rates have been best estimated from next-generation sequencing panels applied to primarily metastatic patients. The rates across various different tumor types from Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), Caris Life Sciences, and Foundation Medicine are shown in the table  (<a class="graphic graphic_table graphicRef122986" href="/d/graphic/122986.html" rel="external">table 1</a>) [<a href="#rid39">39,48</a>].</p><p class="headingAnchor" id="H628058791"><span class="h2">Approach to testing dMMR as a predictive marker</span><span class="headingEndMark"> — </span>The US Food and Drug Administration label for <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for solid tumors that have deficient mismatch repair (dMMR)/MSI-H indicates that the use should be in patients who "have progressed following prior treatment and who have no satisfactory alternative treatment options." For advanced colorectal cancer, there are broader but more clearly delineated indications:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients previously treated with a fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, and <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use in first-line therapy is also approved based upon results of KEYNOTE-177 (NCT02563002), a randomized phase III trial which demonstrated a progression free survival benefit for front-line <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> compared with standard-of-care chemotherapy in first-line dMMR metastatic colorectal cancer. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'</a>.)</p><p></p><p>MSI-H/dMMR testing is appropriate for all patients with colorectal and endometrial cancer as per guideline-based recommendations related to the high rate of Lynch syndrome in these cancer types. In addition, testing other metastatic or advanced tumor types with high rates of MSI-H/dMMR who would be candidates for immunotherapy is appropriate. As an example given that the rate in metastatic colorectal cancer is approximately 4 percent, the testing of cancers with similar rates, such as small bowel adenocarcinoma, gastric cancer, prostate cancer, and biliary cancer, would be one approach for clinical practice  (<a class="graphic graphic_table graphicRef122986" href="/d/graphic/122986.html" rel="external">table 1</a>) [<a href="#rid39">39,48</a>]. More recently, an ASCO provisional clinical opinion recommended the testing of dMMR/MSI-H in all patients with metastatic or advanced solid tumors who would be candidates for immunotherapy [<a href="#rid49">49</a>]. Although the provisional opinion also recommends considering the prevalence of dMMR and/or MSI-H status in individual tumor types before making this decision, given both the high level and durable activity of immunotherapy for treatment of advanced dMMR/MSI-H solid tumors, the authors favor an aggressive approach to testing all metastatic or advanced solid tumors.</p><p>An important point is that regardless of the tumor type, MSI-H or dMMR may indicate the presence of Lynch syndrome. All patients with an MSI-H/dMMR cancer, regardless of age or family history, should undergo workup to determine sporadic or germline etiology [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'</a>.)</p><p class="headingAnchor" id="H1691177428"><span class="h1">APPROACH TO TESTING FOR HIGH LEVELS OF TMB</span><span class="headingEndMark"> — </span>We recommend the use of a large next-generation sequencing (NGS) platform to assess TMB. Interpretation of TMB should be done in the context of the NGS panel utilized and the tumor type tested. At present only the FoundationOne CDx assay has been approved as a companion diagnostic for the tumor agnostic <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> approval for patients with a TMB of ≥10 mutations per megabase (mut/Mb). If another assay for TMB is used, clinicians should review the manufacturer's documentation to confirm the appropriate cutoff to define TMB-high tumors.</p><p>As noted above, a major problem with using TMB as a predictive factor for response to immune checkpoint inhibitors is that the method of determination and thresholds for TMB have been developed independently in each tumor type, and they are likely to differ across tumor types [<a href="#rid27">27</a>] and across platforms [<a href="#rid29">29</a>]; as a result, no consistent pan-cancer testing approach has been validated. The US Food and Drug Administration approval of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for tumors with high levels of TMB specified the use of the FoundationOne CDx assay, and the cutpoint of ≥10 mut/Mb, because this was the assay and threshold used in the seminal KEYNOTE-158 trial. This cutpoint was preselected based upon analyses of data linking TMB to responsiveness to immune checkpoint inhibitor blockade, mainly in lung and urothelial cancer [<a href="#rid11">11-13</a>], and the data employing higher thresholds as a method of improving antitumor efficacy, at least in lung cancer, are disparate [<a href="#rid12">12,13,50</a>]. As a result, TMB alone is not routinely used in NSCLC to make treatment decisions regarding immunotherapy [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a>.)</p><p>However, whether this is the optimal threshold for all other cancers is uncertain, as TMB is a continuous variable [<a href="#rid52">52</a>]. Furthermore, as noted above, there appears to be a tumor tissue-type interaction between TMB and response to immune checkpoint inhibitors that has not been addressed in efficacy studies such as KEYNOTE-158.</p><p>There is a need for harmonization of TMB reporting across different NGS assays currently in use and across various tumor types. In one study investigating TMB estimation from 11 NGS panels compared with known whole exome TMB, certain NGS panels consistently overestimated or underestimated TMB [<a href="#rid27">27</a>]. In part this reflects the differences in NGS panel size, composition, and bioinformatics algorithms. To address this variability the Friends of Cancer Research TMB Harmonization Consortium has recommended best practices for NGS panel developers that include (1) TMB reporting in mutations/megabase, (2) standardized analytical validation studies, and (3) the alignment of NGS panel TMB to universal whole exome sequencing standards [<a href="#rid29">29</a>]. The second phase of their harmonization effort focused on variability across different panels and best practices for panel TMB alignment [<a href="#rid53">53</a>]. Clinicians should review the documentation provided by the vendor in interpreting individual TMB results.</p><p class="headingAnchor" id="H4029743434"><span class="h2">Frequency of high TMB across tumor types</span><span class="headingEndMark"> — </span>The highest levels of mutational load are found in melanomas, non-small cell lung carcinoma, and other squamous carcinomas, and these are also the cancers with the highest percentage of cases with high TMB [<a href="#rid3">3,6</a>]. Intermediate levels and a lower frequency of cases with high TMB are found in breast, uterine ovarian and kidney cancers, prostate and bladder cancers, head and neck cancers, and some subtypes of soft tissue sarcoma. High levels of TMB (variably defined) are found in approximately 12 percent of small bowel adenocarcinomas, and 5 percent of colorectal and gastric cancers [<a href="#rid54">54,55</a>]. The average across all solid tumor types according to data from FoundationOne is 13.3 percent [<a href="#rid6">6</a>].</p><p>In our view, tumoral testing for high levels of TMB is appropriate for any patient with a solid tumor for which there is no longer an appropriate treatment option, and who might be eligible for treatment with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>.</p><p class="headingAnchor" id="H4253131224"><span class="h1">CLINICAL EFFICACY OF ANTI-PD-1 THERAPY</span><span class="headingEndMark"> — </span>Anti-programmed cell death 1 (PD-1) therapy with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was approved for use in solid tumors with high levels of microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) by the US Food and Drug Administration (FDA) in May of 2017 based on the results of one prospective trial [<a href="#rid1">1</a>] and retrospective analyses of five uncontrolled single-arm clinical trials [<a href="#rid56">56</a>]. In some trials, patients were required to have MSI-H or dMMR cancers, while in others, a subgroup of patients was identified as having MSI-H or dMMR cancers by testing tumor samples after treatment had begun. A total of 15 cancer types were identified among 149 patients enrolled across these five clinical trials; the most common were colorectal, endometrial, and other gastrointestinal cancers. Of the 149 patients who received pembrolizumab in the trials, 40 percent had a complete or partial response, and the response lasted for six months or more in 78 percent of those patients [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H899402744"><span class="h2">Tumors with deficient mismatch repair</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors are associated with a high level of activity independent of tumor type and drug used [<a href="#rid57">57</a>]. The following section will review separately the efficacy in colorectal cancer and other tumors with deficiency in mismatch repair.</p><p class="headingAnchor" id="H3859445625"><span class="h3">Metastatic colorectal cancer</span></p><p class="headingAnchor" id="H3281823873"><span class="h4">Pembrolizumab</span><span class="headingEndMark"> — </span>The hypothesis that cancers with dMMR might be particularly susceptible to inhibition of the programmed cell death ligand 1 (PD-L1)/PD-1 interaction was initially provided in a phase II trial in which <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, an immunoglobulin G4 (IgG4) monoclonal antagonist antibody to PD-1, was administered intravenously at a dose of 10 mg/kg every 14 days to 11 patients with dMMR metastatic colorectal cancer, 21 patients with proficient mismatch repair (pMMR) metastatic colorectal cancer, and 9 patients with noncolorectal dMMR metastatic cancers; all had been heavily pretreated [<a href="#rid1">1</a>]. In a later analysis of an expanded cohort of 54 patients with dMMR or pMMR metastatic colorectal cancer, patients with dMMR metastatic colorectal cancer had a 50 percent objective response rate (ORR) and an 89 percent disease control rate (objective response or stable disease) [<a href="#rid48">48</a>]. By contrast, the ORR was 0 percent, and the disease control rate was 16 percent in patients with pMMR metastatic colorectal cancer. After a median treatment duration of 5.9 months, no patients in the dMMR group who had responded had progressed. Overall survival and progression-free survival (PFS) were not reached in the dMMR group, compared with a median PFS of 2.3 months and an overall survival of 7.6 months in the pMMR group.</p><p>Patients with dMMR noncolorectal cancers had responses similar to those of patients with dMMR metastatic colorectal cancers (immune-related ORR 71 percent [5 of 7 patients], immune-related PFS rate 67 percent [4 of 6 patients]) [<a href="#rid1">1</a>].</p><p class="bulletIndent1">Based on these data, the FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for the treatment of patients with advanced unresectable or metastatic MSI-H or dMMR metastatic colorectal cancer [<a href="#rid58">58</a>]. Pembrolizumab is also approved for the treatment of adult and pediatric patients with any advanced or metastatic dMMR or MSI-H solid tumor that has progressed following prior treatment, and who have no satisfactory alternative treatment options [<a href="#rid58">58</a>]. (See <a class="local">'Other tumors with MSI-H/dMMR'</a> below.)</p><p></p><p>High levels of durable antitumor efficacy for <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> have been confirmed in other cohorts, including older adults [<a href="#rid59">59</a>], and in a multicenter phase II trial of patients with previously treated dMMR metastatic colorectal cancer [<a href="#rid48">48,60,61</a>].</p><p class="headingAnchor" id="H3177841619"><span class="h4">Nivolumab with or without ipilimumab</span><span class="headingEndMark"> — </span>Benefit for a second anti-PD-1 monoclonal antibody, both alone and in combination with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, in patients with dMMR metastatic colorectal cancer was suggested in a second trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02060188%3Fterm%3D02060188%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPN%2FBgNo3ueakSH8vSsT6%2FR6zGyJyOmSgAoj1bgjN4aWgHCilyA8lOaclP8AEfMt3jo%3D&amp;TOPIC_ID=120646" target="_blank">CheckMate 142</a>) in which patients with dMMR (n = 59) or pMMR (n = 23) metastatic colorectal cancer received <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (a fully human anti-PD-L1 monoclonal antibody) with or without ipilimumab (a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 [CTLA-4]) [<a href="#rid62">62</a>]. The following results are available:</p><p class="bulletIndent1"><span class="glyph">●</span>In a preliminary report presented at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, immunotherapy with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, with or without <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, benefited those with dMMR tumors (13 confirmed partial responses, median PFS 5.3 months). By contrast, there were no objective responses among those with pMMR tumors, and median PFS was 1.4 months [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a later analysis of 74 patients with dMMR metastatic colorectal cancer treated with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone, 23 had an objective response (31 percent), and the median duration of response had not been reached; eight had responses lasting 12 months or longer [<a href="#rid63">63</a>]. Largely based on these data, in August of 2017, the FDA extended the approval of nivolumab to MSI-H or dMMR metastatic colorectal cancer that progressed following treatment with a fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, and <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid56">56</a>]; the approval was not tissue agnostic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent report suggested an even greater degree of benefit for targeting both PD-1 and CTLA-4 as compared with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> alone [<a href="#rid64">64</a>] in a nonrandomized comparison. Largely based on these data, in July of 2018, the FDA approved the combination of nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> for patients with previously treated MSI-H or dMMR metastatic colorectal cancer. Once again, this approval was not tissue agnostic. Data also support benefit for first-line nivolumab plus ipilimumab in dMMR metastatic colorectal cancer [<a href="#rid65">65</a>].</p><p></p><p>It is currently not known in which patients with MSI-H metastatic colorectal cancer to use combined <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, or whether this combination is active in patients who relapse or progress on single-agent checkpoint inhibitor immunotherapy; data are extremely limited [<a href="#rid66">66</a>].</p><p>The use of checkpoint inhibitors in earlier lines of therapy was addressed in the KEYNOTE-177 trial, a randomized phase III trial of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> compared with standard-of-care chemotherapy in first-line dMMR metastatic colorectal cancer [<a href="#rid67">67</a>]. Pembrolizumab was superior in efficacy (PFS) and better tolerated than conventional front-line chemotherapy for individuals with dMMR tumors, and as a result of these data, pembrolizumab was approved for first-line treatment of dMMR/MSI-H advanced metastatic colorectal cancer. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'</a>.)</p><p class="headingAnchor" id="H969021561"><span class="h3">Other tumors with MSI-H/dMMR</span><span class="headingEndMark"> — </span>Of the three anti-PD-1 monoclonal antibodies approved in the United States for treatment of dMMR/MSI-H cancer (<a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, and <a class="drug drug_general" data-topicid="131441" href="/d/drug information/131441.html" rel="external">dostarlimab</a>), two (pembrolizumab and dostarlimab) have received a tissue agnostic approval for treatment of any advanced dMMR/MSI-H tumor. Nivolumab is approved for treatment of dMMR/MSI-H advanced colorectal cancer.</p><p>Treatment results for anti-PD-1 immunotherapy in a variety of malignancies, and the integration of immune checkpoint inhibitor immunotherapy in the context of the other available therapeutic options for advanced disease of individual histologies are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2473.html" rel="external">"Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'Immunotherapy-based regimens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/121739.html" rel="external">"Second and later-line systemic therapy for advanced unresectable and metastatic esophageal and gastric cancer", section on 'Checkpoint inhibitor immunotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/126055.html" rel="external">"Initial treatment of metastatic endometrial cancer", section on 'MMR deficient or MSI-H tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127094.html" rel="external">"Second-line systemic therapy for advanced exocrine pancreatic cancer", section on 'Deficient mismatch repair or high tumor mutational burden'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2499.html" rel="external">"Treatment of advanced, unresectable gallbladder cancer", section on 'Immunotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2509.html" rel="external">"Treatment of small bowel neoplasms", section on 'Indications for immunotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2524.html" rel="external">"Systemic therapy for advanced cholangiocarcinoma", section on 'Immunotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6937.html" rel="external">"Immunotherapy for castration-resistant prostate cancer", section on 'PD-1 pathway inhibition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/139327.html" rel="external">"Second and later lines of therapy for metastatic soft tissue sarcoma", section on 'Tumors with dMMR, MSI-H, or high levels of TMB'</a>.)</p><p></p><p class="headingAnchor" id="H3154476683"><span class="h4">Pembrolizumab</span><span class="headingEndMark"> — </span>A wide variety of tumor types other than metastatic colorectal cancer that have high levels of microsatellite instability (MSI-H)/deficient mismatch repair (dMMR) may benefit from <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, and the broad FDA approval for this agent supports the use of this agent across a wide spectrum of histologies. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 86 dMMR tumors receiving single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, ORRs, durations of disease control, and overall survivals were similar in the 40 patients with metastatic colorectal cancer when compared with the 46 patients with noncolorectal cancers [<a href="#rid48">48</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ORR of 52 versus 54 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Disease control rate (objective response plus stable disease) of 82 versus 72 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Two-year PFS of 59 versus 46 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Two-year overall survival of 72 versus 57 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second larger cohort of 233 patients with previously treated advanced noncolorectal dMMR tumors (27 different tumor types) receiving <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy in the phase II KEYNOTE-158 study reported substantial antitumor activity for the following tumor types with the greatest enrollment: endometrial cancer, gastric cancer, pancreatic cancer, small intestine cancer, ovarian cancer, and cholangiocarcinoma [<a href="#rid68">68</a>]. Notably, approximately one-third of the patients with an objective antitumor response had a complete response. In a later analysis of this cohort with longer follow-up, the median duration of response among responders was 47.5 months (range 2.1+ to 51.1+) and the percentage of individuals remaining alive ≥3 years following enrollment ranged from 23 to 62 percent; it was highest in those with endometrial, small intestinal, or biliary tract cancer  (<a class="graphic graphic_table graphicRef139972" href="/d/graphic/139972.html" rel="external">table 2</a>) and lowest in those with brain or pancreatic cancer [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H2973779273"><span class="h4">Dostarlimab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131441" href="/d/drug information/131441.html" rel="external">Dostarlimab</a> is used to treat MMR-deficient advanced endometrial cancer. (See  <a class="medical medical_review" href="/d/html/141321.html" rel="external">"Subsequent line systemic therapy for metastatic endometrial cancer", section on 'Tumors with dMMR (MSI-H) or high TMB'</a>.)</p><p>The FDA also granted a tissue-agnostic approval to <a class="drug drug_general" data-topicid="131441" href="/d/drug information/131441.html" rel="external">dostarlimab</a> for any relapsed/refractory dMMR solid tumor [<a href="#rid70">70</a>]. Approval was based on a preliminary report of 106 patients with dMMR nonendometrial solid tumors (93 percent of gastrointestinal [GI] tract origin) treated on the GARNET study with dostarlimab 500 mg intravenously (IV) every three weeks for four courses, then 1000 mg every six weeks until treatment discontinuation [<a href="#rid71">71</a>]. In a preliminary report presented at the 2021 GI ASCO meeting, at a median follow-up of 12.4 months, the confirmed objective response rate was 38.7 percent, with a complete response rate of 7.5 percent. The estimated probability of maintaining a response at 18 months was 81 percent. Severe treatment-related adverse events were experienced by only 5.5 percent, most commonly lipase elevations.</p><p class="headingAnchor" id="H2500302365"><span class="h4">Nivolumab</span><span class="headingEndMark"> — </span>Information on the benefits of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> monotherapy for dMMR noncolorectal cancer is available from a subprotocol arm of the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial [<a href="#rid72">72</a>]. Of the 42 enrolled patients, the most common histologies were endometrial (n = 13) and prostate (n = 5) adenocarcinoma and uterine carcinosarcoma (n = 4). The ORR was 36 percent, and 3 of 15 responses were complete. The estimated 6-, 12-, and 18-month PFS rates were 51, 46, and 31 percent, respectively.</p><p>The combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> has not yet been tested in metastatic MSI-H noncolorectal cancers.</p><p class="headingAnchor" id="H285479745"><span class="h3">Response assessment</span><span class="headingEndMark"> — </span>Individuals treated with immune checkpoint inhibitors for any cancer, can have pseudoprogression within the first several months of treatment, although the incidence is variable, in part related to differences in diseases, treatments, timing of restaging exams, as well as how the concept is defined. Response criteria specifically geared toward these agents (ie, immune-modified RECIST  (<a class="graphic graphic_table graphicRef116649" href="/d/graphic/116649.html" rel="external">table 3</a>)) should be used. These issues are addressed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p class="headingAnchor" id="H4068744871"><span class="h2">Tumors with high mutational burden</span><span class="headingEndMark"> — </span>As noted above, TMB has been of increasing interest as a potential biomarker of benefit from immune checkpoint inhibitor immunotherapy, and several reports now support a link between high levels of TMB and response to anti-PD-1 therapy in a variety of primary tumor types [<a href="#rid11">11,14,20,73-80</a>]. (See <a class="local">'Tumor mutational burden'</a> above.)</p><p>The most compelling data on the predictive capacity of TMB as an independent predictor of the response to immune checkpoint inhibitor immunotherapy come from the multicenter open-label phase II KEYNOTE-158 study, which established a link between TMB-high status (as determined by the FoundationOne CDx assay) and overall response rate with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid80">80</a>]. The trial accrued patients with anal, biliary, cervical, endometrial, salivary, thyroid, or vulvar carcinoma, mesothelioma, a neuroendocrine tumor (NET), or small cell lung cancer (SCLC), who had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and had progressed or were intolerant of at least one prior line of standard therapy. Pembrolizumab was administered at 200 mg IV every three weeks.</p><p>There were 805 patients with evaluable TMB: 105 were TMB-high (defined as TMB ≥10 mutations per megabase [mut/Mb]), 14 of whom were also MSI-H. For TMB-high patients, the ORR (the primary endpoint) was 29 percent, including 28 percent in non-MSI-H patients, while the ORR for TMB-low patients was only 6 percent. Among the TMB-low patients, responses were seen in 33 of 383 (9 percent) of those with PD-L1-positive tumors, and 9 of the 274 (3 percent) who had PD-L1-negative tumors. Some responses were complete. While median PFS was similar for the TMB-high and TMB-low groups (median 2.1 months in each group), the tail of the PFS curve favored TMB-high patients (three-year PFS 32 versus 22 percent of those with TMB-low tumors). Among those with TMB-high tumors, responses were seen in SCLC (10 of 34, 29 percent), cervical cancer (5 of 16, 31 percent), endometrial cancer (7 of 15, 47 percent), NETs (2 of 5, 40 percent), vulvar cancer (2 of 12, 17 percent), anal cancer (1 of 14, 7 percent), thyroid cancer (2 of 2, both complete), and salivary gland cancer (1 of 3, 33 percent). None of the 63 enrolled patients with biliary tract cancer had TMB-high disease.</p><p>Largely based on these results, in June 2020, the FDA approved <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that are tissue TMB-high (≥10 mut/Mb) by an FDA-approved assay (although the FoundationOne CDx assay was used in the supporting KEYNOTE-158 clinical trial), who have progressed following prior therapy, and who have no satisfactory alternative treatment options.</p><p>The FDA label does not explicitly include common tumors (eg, breast, colorectal, gastroesophageal, prostate) as they were not included in the KEYNOTE-158 study. At least some data in advanced colorectal cancer (using a different assay and different TMB threshold) suggest limited objective response rates in TMB-high but microsatellite stable disease [<a href="#rid24">24</a>]; similar findings are reported for advanced esophagogastric cancers [<a href="#rid25">25,81</a>]. Emerging data predominantly focused upon colorectal cancer with pMMR have demonstrated that the rare functional inactivating genomic alterations in DNA polymerase epsilon or delta 1 (<em>POLE</em> or <em>POLD1</em>, collectively referred to as <em>pol-d</em> pathogenic mutations) appear to identify an immune responsive subset of individuals with pMMR colorectal cancer that are TMB-high ≥10 mut/Mb [<a href="#rid32">32-34</a>].</p><p>On the other hand, the available data in breast cancer are conflicting:</p><p class="bulletIndent1"><span class="glyph">●</span>One report from the TAPUR study that included a small number of patients with metastatic breast cancer and high TMB treated with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> noted a 37 percent objective response rate [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another analysis of data from the ARTEMIS study in which women with triple negative breast cancer who did not respond to four courses of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>/<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> were stratified to molecularly targeted therapy or clinicians' choice of treatment, high levels of TMB did not predict for response to immune checkpoint blockade (objective response rate &lt;20 percent), a similar finding to other cancers where the neoantigen load was not positively correlated with CD8 T-cell levels [<a href="#rid83">83</a>].</p><p></p><p>Doubts remain as to whether absolute TMB levels alone are a useful indicator of benefit from immune checkpoint inhibitors for all solid tumor types. A secondary analysis of a series of 1661 patients with various tumors treated with a checkpoint inhibitor at a single institution [<a href="#rid74">74</a>] showed that a TMB cutoff of 10 or more did not predict for benefit from checkpoint inhibitor immunotherapy in most of the limited subgroup of MMR-proficient tumors when stratified according to tumor type [<a href="#rid32">32</a>]. Only patients with metastatic head and neck cancer, non-small cell lung cancer, and melanoma with MMR-proficient high TMB tumors had improved overall survival with immunotherapy.</p><p>These data underscore the high level of tumor type dependency of high levels of TMB; caution is urged in extrapolating the FDA labeling to all tumor types. (See <a class="local">'Approach to testing for high levels of TMB'</a> above.)</p><p>The benefits of dual checkpoint inhibitor blockade is under study, but the data are so far less than definitive. Although a meta-analysis suggests that TMB predicts benefit for combined therapy that targets two different immune checkpoints (CTLA-4 and PD-1/PD-L1) [<a href="#rid26">26</a>], individual studies have not always shown this association [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H2933839012"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deficient mismatch repair</strong> – Deficient mismatch repair (dMMR) and its characteristic genetic signature, high levels of microsatellite instability (MSI-H), define a unique biologic subset of cancers that have a high tumor mutational load and responsiveness to immune checkpoint inhibitor immunotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tissue-agnostic approvals</strong> – <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> and <a class="drug drug_general" data-topicid="131441" href="/d/drug information/131441.html" rel="external">dostarlimab</a>, which are programmed cell death-1 (PD-1) inhibitors, are approved by the US Food and Drug Administration (FDA) for the treatment of patients with dMMR/MSI-H solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (See <a class="local">'Other tumors with MSI-H/dMMR'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessment of dMMR</strong> – dMMR can be assessed by either direct immunohistochemical testing (IHC) for loss of the various mismatch repair proteins (mutL homolog 1 [MLH1], mutS homolog 2 [MSH2], mutS homolog 6 [MSH6], and postmeiotic segregation increased 2 [PMS2]) or by a comparison of the variation in length of a limited number of microsatellites between normal and tumor tissue by polymerase chain reaction (PCR). It can also be assessed by next-generation sequencing (NGS). (See <a class="local">'Assessing mismatch repair'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with colorectal cancer, assessment by any of these methods is acceptable.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For cancers other than colorectal cancer, we recommend the use of IHC or NGS panels rather than PCR for microsatellite instability when evaluating for dMMR/MSI-H.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for testing</strong> – Given that anti-PD-1 therapy is used for the treatment of metastatic disease, the prevalence of dMMR/MSI-H across metastatic cancers is of greatest relevance to clinical care. An estimate of the frequency of dMMR across several tumor types, as derived from NGS panels applied to primarily metastatic patients, is presented in the table  (<a class="graphic graphic_table graphicRef122986" href="/d/graphic/122986.html" rel="external">table 1</a>). (See <a class="local">'Frequency of dMMR across tumor types'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Given the approval of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for front-line therapy, testing for dMMR/MSI-H should be undertaken for all patients with advanced colorectal cancer prior to initiating front-line therapy for metastatic disease. (See <a class="local">'Metastatic colorectal cancer'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>However, given the broad indication for <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> and <a class="drug drug_general" data-topicid="131441" href="/d/drug information/131441.html" rel="external">dostarlimab</a> in a variety of dMMR solid tumors, and the high level and durability of responses to immunotherapy in dMMR tumors, we favor a more universal testing approach that includes for all metastatic or advanced tumors if the individual would be a candidate for immunotherapy. (See <a class="local">'Approach to testing dMMR as a predictive marker'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High levels of tumor mutational burden (TMB)</strong> – Tumors with high mutational burden (particularly those arising in the setting of dMMR) are thought to be more immunogenic and responsive to immune checkpoint inhibitor immunotherapy. (See <a class="local">'Tumor mutational burden'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tissue-agnostic approvals</strong> – Based upon an early report of the KEYNOTE-158 trial, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is approved for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that are tissue TMB-high (≥10 mutations per megabase [mut/Mb]) by an FDA-approved assay, and who have progressed following prior therapy and who have no satisfactory alternative treatment options. (See <a class="local">'Tumors with high mutational burden'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessment of TMB</strong> – We suggest the use of a threshold TMB of ≥10 mut/Mb if the NGS platform FoundationOne CDx assay is used, to select patients for immune checkpoint inhibitor immunotherapy, as was done in KEYNOTE-158. As other assays and platforms are now reporting TMB, clinicians should refer to the manufacturer's information to identify the specific cutoff for that assay to define TMB-high tumors. (See <a class="local">'Approach to testing for high levels of TMB'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for testing</strong> – In our view, tumoral testing for high levels of TMB is appropriate for any patient with a solid tumor for which there is no longer an appropriate treatment option, and who might be eligible for treatment with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>. (See <a class="local">'Frequency of high TMB across tumor types'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509.</a></li><li><a class="nounderline abstract_t">Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res 2016; 22:813.</a></li><li><a class="nounderline abstract_t">Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017; 9:34.</a></li><li><a class="nounderline abstract_t">Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 2019; 37:286.</a></li><li><a class="nounderline abstract_t">Yarchoan M, Johnson BA 3rd, Lutz ER, et al. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017; 17:209.</a></li><li><a class="nounderline abstract_t">Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019; 30:44.</a></li><li><a class="nounderline abstract_t">Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400.</a></li><li><a class="nounderline abstract_t">Riaz N, Morris L, Havel JJ, et al. The role of neoantigens in response to immune checkpoint blockade. Int Immunol 2016; 28:411.</a></li><li><a class="nounderline abstract_t">Giannakis M, Mu XJ, Shukla SA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep 2016; 17:1206.</a></li><li><a class="nounderline abstract_t">Oh DY, Venook AP, Fong L. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw 2015; 13:970.</a></li><li><a class="nounderline abstract_t">Ready N, Hellmann MD, Awad MM, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol 2019; 37:992.</a></li><li><a class="nounderline abstract_t">Hellmann MD, Callahan MK, Awad MM, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 2018; 33:853.</a></li><li><a class="nounderline abstract_t">Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 2018; 24:1441.</a></li><li><a class="nounderline abstract_t">Goodman AM, Kato S, Bazhenova L, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 2017; 16:2598.</a></li><li><a class="nounderline abstract_t">Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189.</a></li><li><a class="nounderline abstract_t">Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124.</a></li><li><a class="nounderline abstract_t">Richard C, Fumet JD, Chevrier S, et al. Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Clin Cancer Res 2019; 25:957.</a></li><li><a class="nounderline abstract_t">Kim JY, Kronbichler A, Eisenhut M, et al. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019; 11.</a></li><li><a class="nounderline abstract_t">Wu Y, Xu J, Du C, et al. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2019; 9:1161.</a></li><li><a class="nounderline abstract_t">Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 2017; 377:2500.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803.</a></li><li><a class="nounderline abstract_t">Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol 2017; 35:3851.</a></li><li><a class="nounderline abstract_t">Labriola MK, Zhu J, Gupta RT, et al. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Duvivier HL, Rothe M, Mangat PK, et al. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol 2023; 41:5140.</a></li><li><a class="nounderline abstract_t">Shitara K, Özgüroğlu M, Bang YJ, et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol 2021; 32:1127.</a></li><li><a class="nounderline abstract_t">Osipov A, Lim SJ, Popovic A, et al. Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. Clin Cancer Res 2020; 26:4842.</a></li><li><a class="nounderline abstract_t">Fernandez EM, Eng K, Beg S, et al. Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO Precis Oncol 2019; 3.</a></li><li><a class="nounderline abstract_t">Valero C, Lee M, Hoen D, et al. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncol 2021; 7:739.</a></li><li><a class="nounderline abstract_t">Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Si H, Kuziora M, Quinn KJ, et al. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clin Cancer Res 2021; 27:1631.</a></li><li><a class="nounderline abstract_t">Wang J, Xiu J, Farrell A, et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol 2023; 24:151.</a></li><li><a class="nounderline abstract_t">Rousseau B, Foote MB, Maron SB, et al. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. N Engl J Med 2021; 384:1168.</a></li><li><a class="nounderline abstract_t">Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol 2019; 5:1504.</a></li><li><a class="nounderline abstract_t">Rousseau B, Bieche I, Pasmant E, et al. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discov 2022; 12:1435.</a></li><li><a class="nounderline abstract_t">Vikas P, Messersmith H, Compton C, et al. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol 2023; 41:1943.</a></li><li><a class="nounderline abstract_t">Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261.</a></li><li><a class="nounderline abstract_t">Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89:1758.</a></li><li><a class="nounderline abstract_t">Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248.</a></li><li><a class="nounderline abstract_t">Middha S, Zhang L, Nafa K, et al. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precis Oncol 2017; 2017.</a></li><li><a class="nounderline abstract_t">Hall MJ, Gowen K, Sanford EM, et al. Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP). J Clin Oncol 2017; 34:528.</a></li><li><a class="nounderline abstract_t">Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 2018; 7:746.</a></li><li><a class="nounderline abstract_t">Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 2014; 30:1015.</a></li><li><a class="nounderline abstract_t">Huang MN, McPherson JR, Cutcutache I, et al. MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Sci Rep 2015; 5:13321.</a></li><li><a class="nounderline abstract_t">Nowak JA, Yurgelun MB, Bruce JL, et al. Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. J Mol Diagn 2017; 19:84.</a></li><li><a class="nounderline abstract_t">Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 2016; 22:1342.</a></li><li><a class="nounderline abstract_t">Hempelmann JA, Lockwood CM, Konnick EQ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer 2018; 6:29.</a></li><li><a class="nounderline abstract_t">Bonneville R, Krook MA, Kautto EA, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol 2017; 2017.</a></li><li><a class="nounderline abstract_t">Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357:409.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Ricciuti B, Wang X, Alessi JV, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol 2022; 8:1160.</a></li><li><a class="nounderline abstract_t">Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 2018; 36:633.</a></li><li><a class="nounderline abstract_t">Manca P, Corti F, Intini R, et al. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer 2023; 187:15.</a></li><li><a class="nounderline abstract_t">Vega DM, Yee LM, McShane LM, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol 2021; 32:1626.</a></li><li><a class="nounderline abstract_t">Schrock AB, Devoe CE, McWilliams R, et al. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 2017; 3:1546.</a></li><li><a class="nounderline abstract_t">Parikh AR, He Y, Hong TS, et al. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist 2019; 24:1340.</a></li><li class="breakAll">OPDIVO (nivolumab) injection, 40 mg/4 mL and 100 mg/10 mL. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125554Orig1s034ltr.pdf (Accessed on August 04, 2017).</li><li><a class="nounderline abstract_t">Petrelli F, Ghidini M, Ghidini A, Tomasello G. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis. JAMA Oncol 2020; 6:1068.</a></li><li class="breakAll">Pembrolizumab: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s132lbl.pdf (Accessed on April 03, 2023).</li><li><a class="nounderline abstract_t">Saberzadeh-Ardestani B, Jones JC, Hubbard JM, et al. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. JAMA Netw Open 2023; 6:e230400.</a></li><li><a class="nounderline abstract_t">Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol 2020; 38:11.</a></li><li><a class="nounderline abstract_t">Le DT, Diaz LA Jr, Kim TW, et al. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer 2023; 186:185.</a></li><li><a class="nounderline abstract_t">Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol 2016; 34S: ASCO #3501.</a></li><li><a class="nounderline abstract_t">Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18:1182.</a></li><li><a class="nounderline abstract_t">Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 2018; 36:773.</a></li><li><a class="nounderline abstract_t">Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol 2022; 40:161.</a></li><li><a class="nounderline abstract_t">Winer A, Ghatalia P, Bubes N, et al. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. Oncologist 2019; 24:1416.</a></li><li><a class="nounderline abstract_t">André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383:2207.</a></li><li><a class="nounderline abstract_t">Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38:1.</a></li><li><a class="nounderline abstract_t">Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33:929.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761223Orig1s000ltr.pdf (Accessed on August 19, 2021).</li><li class="breakAll">Andre T, Berton D. Curigliano G, et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: results from the Garnet study (abstract). J Clin Oncol  39, 2021 (suppl 3; abstr 9). Abstract available online at https://meetinglibrary.asco.org/record/194077/abstract (Accessed on August 19, 2021).</li><li><a class="nounderline abstract_t">Azad NS, Gray RJ, Overman MJ, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol 2020; 38:214.</a></li><li><a class="nounderline abstract_t">Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol 2019; 37:318.</a></li><li><a class="nounderline abstract_t">Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51:202.</a></li><li><a class="nounderline abstract_t">Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018; 378:2093.</a></li><li><a class="nounderline abstract_t">Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018; 362.</a></li><li><a class="nounderline abstract_t">Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol 2019; 30:1096.</a></li><li><a class="nounderline abstract_t">Greally M, Chou JF, Chatila WK, et al. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clin Cancer Res 2019; 25:6160.</a></li><li><a class="nounderline abstract_t">Aggarwal C, Thompson JC, Chien AL, et al. Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 2020; 26:2354.</a></li><li><a class="nounderline abstract_t">Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21:1353.</a></li><li><a class="nounderline abstract_t">Foote MB, Maron SB, Cercek A, et al. TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061. Ann Oncol 2021; 32:1188.</a></li><li><a class="nounderline abstract_t">Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol 2021; 39:2443.</a></li><li><a class="nounderline abstract_t">McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 2021; 32:661.</a></li></ol></div><div id="topicVersionRevision">Topic 120646 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26028255" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26880610" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Microsatellite Instability as a Biomarker for PD-1 Blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28420421" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376427" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233802" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Targeting neoantigens to augment antitumour immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30395155" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318521" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048318" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The role of neoantigens in response to immune checkpoint blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27760322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26285242" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : On the Verge: Immunotherapy for Colorectal Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30785829" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29731394" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30082870" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835386" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25409260" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetic basis for clinical response to CTLA-4 blockade in melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25765070" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30154227" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31731749" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31750249" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29262275" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tumor Mutational Burden and Response Rate to PD-1 Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26406148" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28678668" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32221016" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37561967" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34082019" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32586938" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31475242" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33599686" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217756" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33355200" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36681091" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761214" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31415061" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35398880" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36603179" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970275" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392616" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9823339" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30211344" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29436178" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24371154" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26306458" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863258" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27694933" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Classification and characterization of microsatellite instability across 18 cancer types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29665853" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Microsatellite instability in prostate cancer by PCR or next-generation sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850653" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Landscape of Microsatellite Instability Across 39 Cancer Types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28596308" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35708671" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29337640" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37099945" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34606929" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28617917" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Genomic Profiling of Small-Bowel Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31040255" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31040255" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407439" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407439" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36811859" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31725351" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37141828" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nivolumab±ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28734759" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355075" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34637336" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31444293" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264544" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682550" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35680043" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35680043" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35680043" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31765263" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557521" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30643254" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Tumor mutational load predicts survival after immunotherapy across multiple cancer types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29658845" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30309915" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31038663" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31337644" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32102950" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32919526" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34139271" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33844595" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33736924" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
